In the last 12 months, insiders at CERO THERAPEUTICS HOLDINGS, INC. ($CERO) filed 105 transactions with the SEC: 0 open-market purchases totaling $0 and 8 sales totaling $1,164,365. Net insider sentiment: net selling.
CERO THERAPEUTICS HOLDINGS, INC. operates in the Biological products, (no disgnostic substances) industry (Life sciences sector).
Most Active Insiders
- Ehrlich Christopher B (Director) — 12 transactions totaling $3,385,000
- PHOENIX BIOTECH SPONSOR, LLC (TenPercentOwner) — 6 transactions totaling $3,110,000
- ATWOOD BRIAN G (Chief Executive Officer) — 12 transactions totaling $3,006,000
- YK Bioventures Opportunities GP I, LLC (Not found) — 7 transactions totaling $1,108,826
- ATWOOD BRIAN G (Director) — 15 transactions totaling $1,002,033
View all SEC Filings for CERO THERAPEUTICS HOLDINGS, INC. (CERO).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 7, 2026 | KUCHARCHUK ANDREW ALBERT | Chief Financial Officer | A | Stock Option (Right to Buy) | 1162099 | $0.00 | 1,162,099.0000 | 1,264,884 | 9999.99% | 91.87% |
| Jan. 7, 2026 | Pierce Kristen | Chief Development Officer | A | Stock Option (Right to Buy) | 1612099 | $0.00 | 1,612,099.0000 | 1,264,884 | 9999.99% | 100.00% |
| Jan. 7, 2026 | Rolfe Lindsey | Director | A | Stock Option (Right to Buy) | 690900 | $0.00 | 690,900.0000 | 1,264,884 | 9999.99% | 54.62% |
| Jan. 7, 2026 | LAPORTE KATHLEEN | Director | A | Stock Option (Right to Buy) | 690900 | $0.00 | 690,900.0000 | 1,264,884 | 9999.99% | 54.62% |
| Jan. 7, 2026 | Patel Shami | Director | A | Stock Option (Right to Buy) | 690900 | $0.00 | 690,900.0000 | 1,264,884 | 9999.99% | 54.62% |
| Jan. 7, 2026 | ATWOOD BRIAN G | Director | A | Stock Option (Right to Buy) | 1612099 | $0.00 | 1,612,099.0000 | 1,264,884 | 9999.99% | 100.00% |
| Jan. 7, 2026 | Ehrlich Christopher B | Chairman and CEO | A | Stock Option (Right to Buy) | 4530997 | $0.00 | 4,530,997.0000 | 1,264,884 | 9999.99% | 100.00% |
| Jan. 7, 2026 | Byrnes Michael | Director | A | Stock Option (Right to Buy) | 690900 | $0.00 | 690,900.0000 | 1,264,884 | 9999.99% | 54.62% |
| May 30, 2025 | LAPORTE KATHLEEN | Director | A | Stock Option (Right to Buy) | 9326 | $0.00 | 9,326.0000 | 3,427,616 | 9999.99% | 0.27% |
| May 30, 2025 | Rolfe Lindsey | Director | A | Stock Option (Right to Buy) | 9326 | $0.00 | 9,326.0000 | 3,427,616 | 9999.99% | 0.27% |
| May 30, 2025 | KUCHARCHUK ANDREW ALBERT | Chief Financial Officer | A | Stock Option (Right to Buy) | 152500 | $0.00 | 152,500.0000 | 3,427,616 | 9999.99% | 4.45% |
| May 30, 2025 | Pierce Kristen | Chief Development Officer | A | Stock Option (Right to Buy) | 154841 | $0.00 | 154,841.0000 | 3,427,616 | 9999.99% | 4.52% |
| May 30, 2025 | ATWOOD BRIAN G | Director | A | Stock Option (Right to Buy) | 122549 | $0.00 | 122,549.0000 | 3,427,616 | 9999.99% | 3.58% |
| May 30, 2025 | Ehrlich Christopher B | Chairman and CEO | A | Stock Option (Right to Buy) | 61843 | $0.00 | 61,842.0000 | 3,427,616 | 0.00% | 1.80% |
| May 30, 2025 | Patel Shami | Director | A | Stock Option (Right to Buy) | 11693 | $0.00 | 11,693.0000 | 3,427,616 | 9999.99% | 0.34% |
| May 30, 2025 | Byrnes Michael | Director | A | Stock Option (Right to Buy) | 9326 | $0.00 | 9,326.0000 | 3,427,616 | 9999.99% | 0.27% |
| March 31, 2025 | ATWOOD BRIAN G | Director | M | Common Stock | 294460 | $0.00 | 491,784.0000 | 579,432 | 149.23% | 50.82% |
| March 31, 2025 | ATWOOD BRIAN G | Director | M | Pre-Funded Warrant | 294460 | $0.00 | 215,740.0000 | 579,432 | 0.00% | 50.82% |
| March 4, 2025 | Byrnes Michael | Director | A | Stock Option (Right to Buy) | 17923 | $0.00 | 17,923.0000 | 579,432 | 9999.99% | 3.09% |
| March 4, 2025 | Patel Shami | Director | A | Stock Option (Right to Buy) | 14936 | $0.00 | 14,936.0000 | 579,432 | 9999.99% | 2.58% |
| March 4, 2025 | ATWOOD BRIAN G | Director | A | Stock Option (Right to Buy) | 14936 | $0.00 | 14,936.0000 | 579,432 | 9999.99% | 2.58% |
| March 4, 2025 | Ehrlich Christopher B | Chairman and CEO | A | Stock Option (Right to Buy) | 119486 | $0.00 | 119,486.0000 | 579,432 | 9999.99% | 20.62% |
| March 4, 2025 | LAPORTE KATHLEEN | Director | A | Stock Option (Right to Buy) | 17923 | $0.00 | 17,923.0000 | 579,432 | 9999.99% | 3.09% |
| March 4, 2025 | Rolfe Lindsey | Director | A | Stock Option (Right to Buy) | 17923 | $0.00 | 17,923.0000 | 579,432 | 9999.99% | 3.09% |
| Feb. 24, 2025 | LAPORTE KATHLEEN | Director | A | Stock Option (Right to Buy) | 127500 | $0.00 | 255,000.0000 | 579,432 | 100.00% | 22.00% |
| Feb. 24, 2025 | Ehrlich Christopher B | Chairman and CEO | A | Stock Option (Right to Buy) | 1275000 | $0.00 | 2,550,000.0000 | 579,432 | 100.00% | 100.00% |
| Feb. 24, 2025 | Byrnes Michael | Director | A | Stock Option (Right to Buy) | 127500 | $0.00 | 255,000.0000 | 579,432 | 100.00% | 22.00% |
| Feb. 24, 2025 | ATWOOD BRIAN G | Director | A | Stock Option (Right to Buy) | 254000 | $0.00 | 508,000.0000 | 579,432 | 100.00% | 43.84% |
| Feb. 24, 2025 | Patel Shami | Director | A | Stock Option (Right to Buy) | 127500 | $0.00 | 255,000.0000 | 579,432 | 100.00% | 22.00% |
| Feb. 24, 2025 | Rolfe Lindsey | Director | A | Stock Option (Right to Buy) | 127500 | $0.00 | 255,000.0000 | 579,432 | 100.00% | 22.00% |
| Feb. 7, 2025 | ATWOOD BRIAN G | Director | A | Warrant to Purchase Shares of Common Stock | 204080 | $1.96 | 510,200.0000 | 579,432 | 66.67% | 35.22% |
| Feb. 7, 2025 | ATWOOD BRIAN G | Director | A | Pre-Funded Warrant | 306120 | $0.00 | 510,200.0000 | 579,432 | 150.00% | 52.83% |
| Feb. 7, 2025 | ATWOOD BRIAN G | Director | A | Warrant to Purchase Shares of Common Stock | 306120 | $1.96 | 510,200.0000 | 579,432 | 150.00% | 52.83% |
| Feb. 7, 2025 | ATWOOD BRIAN G | Director | A | Pre-Funded Warrant | 204080 | $0.00 | 510,200.0000 | 579,432 | 66.67% | 35.22% |
| Dec. 12, 2024 | YK Bioventures Opportunities GP I, LLC | Not found | S | Common Stock | 1614541 | $0.07 | 16,004,077.0000 | 24,838 | 9.16% | 100.00% |
| Dec. 11, 2024 | YK Bioventures Opportunities GP I, LLC | Not found | S | Common Stock | 1343801 | $0.08 | 17,618,618.0000 | 24,838 | 7.09% | 100.00% |
| Dec. 13, 2024 | YK Bioventures Opportunities GP I, LLC | Not found | S | Common Stock | 2998908 | $0.06 | 13,005,169.0000 | 24,838 | 18.74% | 100.00% |
| Dec. 6, 2024 | YK Bioventures Opportunities GP I, LLC | Not found | S | Common Stock | 1236874 | $0.12 | 21,383,909.0000 | 24,838 | 5.47% | 100.00% |
| Dec. 9, 2024 | YK Bioventures Opportunities GP I, LLC | Not found | S | Common Stock | 850543 | $0.11 | 20,533,366.0000 | 24,838 | 3.98% | 100.00% |
| Dec. 10, 2024 | YK Bioventures Opportunities GP I, LLC | Not found | S | Common Stock | 1570947 | $0.09 | 18,962,419.0000 | 24,838 | 7.65% | 100.00% |
| Dec. 2, 2024 | LAPORTE KATHLEEN | Director | A | Stock Option (Right to Buy) | 127500 | $0.00 | 127,500.0000 | 24,838 | 9999.99% | 100.00% |
| Dec. 2, 2024 | Ehrlich Christopher B | Chairman and CEO | A | Stock Option (Right to Buy) | 1275000 | $0.00 | 1,275,000.0000 | 24,838 | 9999.99% | 100.00% |
| Dec. 2, 2024 | Rolfe Lindsey | Director | A | Stock Option (Right to Buy) | 127500 | $0.00 | 127,500.0000 | 24,838 | 9999.99% | 100.00% |
| Dec. 2, 2024 | Patel Shami | Director | A | Stock Option (Right to Buy) | 127500 | $0.00 | 127,500.0000 | 24,838 | 9999.99% | 100.00% |
| Dec. 2, 2024 | Byrnes Michael | Director | A | Stock Option (Right to Buy) | 127500 | $0.00 | 127,500.0000 | 24,838 | 9999.99% | 100.00% |
| Dec. 2, 2024 | ATWOOD BRIAN G | Director | A | Stock Option (Right to Buy) | 254000 | $0.00 | 254,000.0000 | 24,838 | 9999.99% | 100.00% |
| Sept. 25, 2024 | SLOAN STUART M | TenPercentOwner | S | Common Stock, $0.0001 par value per share | 532486 | $0.10 | 21,067,956.0000 | 8,099 | 2.47% | 100.00% |
| Oct. 10, 2024 | YK Bioventures Opportunities GP I, LLC | Not found | S | Common Stock | 3250000 | $0.10 | 22,620,783.0000 | 24,838 | 12.56% | 100.00% |
| Sept. 30, 2024 | ATWOOD BRIAN G | Director | D | Stock Option (Right to Buy) | 13857 | $0.00 | 0.0000 | 8,099 | 100.00% | 100.00% |
| Sept. 30, 2024 | ATWOOD BRIAN G | Director | D | Stock Option (Right to Buy) | 1317956 | $0.00 | 0.0000 | 8,099 | 100.00% | 100.00% |
| Oct. 1, 2024 | KUCHARCHUK ANDREW ALBERT | Chief Financial Officer | A | Stock Option (Right to Buy) | 500000 | $0.00 | 500,000.0000 | 24,838 | 9999.99% | 100.00% |
| Oct. 1, 2024 | Pierce Kristen | Chief Development Officer | A | Stock Option (Right to Buy) | 200000 | $0.00 | 200,000.0000 | 24,838 | 9999.99% | 100.00% |
| Sept. 25, 2024 | ATWOOD BRIAN G | Director | M | Series A Convertible Preferred Stock | 1002 | $1000.00 | 0.0000 | 8,099 | 100.00% | 12.37% |
| Sept. 25, 2024 | ATWOOD BRIAN G | Director | M | Common Stock | 19358578 | $0.00 | 19,732,313.0000 | 8,099 | 5179.76% | 100.00% |
| Sept. 30, 2024 | Ehrlich Christopher B | Interim Chairman and CEO | D | Stock Option (Right to Buy) | 572182 | $0.00 | 0.0000 | 8,099 | 100.00% | 100.00% |
| Sept. 25, 2024 | Ehrlich Christopher B | Interim Chairman and CEO | M | Series A Convertible Preferred Stock | 275 | $1000.00 | 0.0000 | 8,099 | 100.00% | 3.40% |
| Sept. 25, 2024 | Ehrlich Christopher B | Interim Chairman and CEO | M | Common Stock | 5312983 | $0.00 | 5,795,408.0000 | 8,099 | 1101.31% | 100.00% |
| Sept. 25, 2024 | LAPORTE KATHLEEN | Director | M | Series A Convertible Preferred Stock | 50 | $1000.00 | 0.0000 | 8,099 | 100.00% | 0.62% |
| Sept. 25, 2024 | LAPORTE KATHLEEN | Director | M | Common Stock | 965997 | $0.00 | 971,825.0000 | 8,099 | 9999.99% | 100.00% |
| June 28, 2024 | Carter Charles Ross | Chief Financial Officer | A | Stock Option (Right to Buy) | 100000 | $0.00 | 100,000.0000 | 141,125 | 9999.99% | 70.86% |
| March 25, 2024 | Rapaport Robyn | Director | A | Stock Option (Right to Buy) | 112500 | $0.00 | 112,500.0000 | 292 | 9999.99% | 100.00% |
| March 25, 2024 | Rolfe Lindsey | Director | A | Stock Option (Right to Buy) | 112500 | $0.00 | 112,500.0000 | 292 | 9999.99% | 100.00% |
| March 25, 2024 | Byrnes Michael | Director | A | Stock Option (Right to Buy) | 112500 | $0.00 | 112,500.0000 | 292 | 9999.99% | 100.00% |
| March 25, 2024 | Carter Charles Ross | Chief Financial Officer | A | Stock Option (Right to Buy) | 395387 | $0.00 | 395,387.0000 | 292 | 9999.99% | 100.00% |
| March 25, 2024 | Corey Daniel | Chief Technical Officer | A | Stock Option (Right to Buy) | 856671 | $0.00 | 856,671.0000 | 292 | 9999.99% | 100.00% |
| March 25, 2024 | Ehrlich Christopher B | Director | A | Stock Option (Right to Buy) | 572182 | $0.00 | 572,182.0000 | 292 | 9999.99% | 100.00% |
| March 25, 2024 | LAPORTE KATHLEEN | Director | A | Stock Option (Right to Buy) | 112500 | $0.00 | 112,500.0000 | 292 | 9999.99% | 100.00% |
| March 25, 2024 | ATWOOD BRIAN G | Chief Executive Officer | A | Stock Option (Right to Buy) | 1317956 | $0.00 | 1,317,956.0000 | 292 | 9999.99% | 100.00% |
| Feb. 14, 2024 | ATWOOD BRIAN G | Chief Executive Officer | J | Common Stock | 148208 | $0.00 | 248,735.0000 | 292 | 147.43% | 100.00% |
| Feb. 14, 2024 | ATWOOD BRIAN G | Chief Executive Officer | A | Stock Option (Right to Buy) | 13857 | $0.00 | 13,857.0000 | 292 | 9999.99% | 100.00% |
| Feb. 14, 2024 | ATWOOD BRIAN G | Chief Executive Officer | A | Series A Convertible Preferred Stock | 1002 | $1000.00 | 1,002.0000 | 292 | 9999.99% | 100.00% |
| Feb. 14, 2024 | ATWOOD BRIAN G | Chief Executive Officer | J | Common Stock | 100527 | $0.00 | 100,527.0000 | 292 | 9999.99% | 100.00% |
| Feb. 14, 2024 | ATWOOD BRIAN G | Chief Executive Officer | J | Common Stock | 100527 | $0.00 | 100,527.0000 | 292 | 9999.99% | 100.00% |
| Feb. 14, 2024 | ATWOOD BRIAN G | Chief Executive Officer | A | Series A Convertible Preferred Stock | 1002 | $1000.00 | 1,002.0000 | 292 | 9999.99% | 100.00% |
| Feb. 14, 2024 | LAPORTE KATHLEEN | Director | A | Series A Convertible Preferred Stock | 50 | $1000.00 | 50.0000 | 292 | 9999.99% | 17.12% |
| Feb. 14, 2024 | ATWOOD BRIAN G | Chief Executive Officer | J | Common Stock | 148208 | $0.00 | 248,735.0000 | 292 | 147.43% | 100.00% |
| Feb. 14, 2024 | Ehrlich Christopher B | Director | M | Convertible Promissory Note | 0 | $0.00 | 0.0000 | 292 | 0.00% | 0.00% |
| Feb. 14, 2024 | Ehrlich Christopher B | Director | M | Series A Convertible Preferred Stock | 1555 | $1000.00 | 1,830.0000 | 292 | 565.45% | 100.00% |
| Feb. 14, 2024 | Ehrlich Christopher B | Director | J | Series A Convertible Preferred Stock | 1555 | $1000.00 | 275.0000 | 292 | 84.97% | 100.00% |
| Feb. 14, 2024 | Ehrlich Christopher B | Director | A | Series A Convertible Preferred Stock | 100 | $1000.00 | 100.0000 | 292 | 9999.99% | 34.25% |
| Feb. 14, 2024 | Ehrlich Christopher B | Director | J | Series A Convertible Preferred Stock | 175 | $1000.00 | 275.0000 | 292 | 175.00% | 59.93% |
| Feb. 14, 2024 | Ehrlich Christopher B | Director | J | Warrants | 349998 | $0.00 | 5,000.0000 | 292 | 98.59% | 100.00% |
| Feb. 14, 2024 | Ehrlich Christopher B | Director | J | Warrants | 5000 | $0.00 | 5,000.0000 | 292 | 9999.99% | 100.00% |
| Feb. 14, 2024 | Ehrlich Christopher B | Director | J | Common Stock | 478825 | $0.00 | 1,482,425.0000 | 292 | 47.71% | 100.00% |
| Feb. 14, 2024 | LAPORTE KATHLEEN | Director | J | Common Stock | 5828 | $0.00 | 5,828.0000 | 292 | 9999.99% | 100.00% |
| Feb. 14, 2024 | LAPORTE KATHLEEN | Director | A | Series A Convertible Preferred Stock | 50 | $1000.00 | 50.0000 | 292 | 9999.99% | 17.12% |
| Feb. 14, 2024 | ATWOOD BRIAN G | Chief Executive Officer | J | Common Stock | 125000 | $0.00 | 373,735.0000 | 292 | 50.25% | 100.00% |
| Feb. 14, 2024 | ATWOOD BRIAN G | Chief Executive Officer | J | Common Stock | 100527 | $0.00 | 225,527.0000 | 292 | 80.42% | 100.00% |
| Feb. 14, 2024 | ATWOOD BRIAN G | Chief Executive Officer | J | Common Stock | 148208 | $0.00 | 373,735.0000 | 292 | 65.72% | 100.00% |
| Feb. 14, 2024 | ATWOOD BRIAN G | Chief Executive Officer | A | Series A Convertible Preferred Stock | 1002 | $1000.00 | 1,002.0000 | 292 | 9999.99% | 100.00% |
| Feb. 14, 2024 | Loewy Caroline M | Director | J | Class A Common Stock | 5828 | $0.00 | 5,828.0000 | 292 | 9999.99% | 100.00% |
| Feb. 14, 2024 | Kosacz Barbara | Director | J | Class A Common Stock | 5828 | $0.00 | 5,828.0000 | 292 | 9999.99% | 100.00% |
| Feb. 14, 2024 | Geffken Daniel E. | Chief Financial Officer | J | Class A Common Stock | 10002 | $0.00 | 10,002.0000 | 292 | 9999.99% | 100.00% |
| Feb. 14, 2024 | Fisher Douglas Carl | President | J | Class A Common Stock | 43300 | $0.00 | 43,300.0000 | 292 | 9999.99% | 100.00% |
| Feb. 14, 2024 | Fisher Douglas Carl | President | A | Series A Convertible Preferred Stock | 50 | $1000.00 | 50.0000 | 292 | 9999.99% | 17.12% |
| Feb. 14, 2024 | Fisher Douglas Carl | President | J | Warrants | 5000 | $0.00 | 5,000.0000 | 292 | 9999.99% | 100.00% |
| Feb. 14, 2024 | PHOENIX BIOTECH SPONSOR, LLC | TenPercentOwner | J | Common Stock | 1125000 | $0.00 | 4,171,246.0000 | 292 | 21.24% | 100.00% |
| Feb. 14, 2024 | PHOENIX BIOTECH SPONSOR, LLC | TenPercentOwner | J | Common Stock | 4171246 | $0.00 | 1,000,000.0000 | 292 | 80.66% | 100.00% |
| Feb. 14, 2024 | PHOENIX BIOTECH SPONSOR, LLC | TenPercentOwner | M | Convertible Promissory Note | 0 | $0.00 | 0.0000 | 292 | 0.00% | 0.00% |
| Feb. 14, 2024 | PHOENIX BIOTECH SPONSOR, LLC | TenPercentOwner | M | Series A Convertible Preferred Stock | 1555 | $1000.00 | 1,555.0000 | 292 | 9999.99% | 100.00% |
| Feb. 14, 2024 | PHOENIX BIOTECH SPONSOR, LLC | TenPercentOwner | J | Series A Convertible Preferred Stock | 1555 | $1000.00 | 0.0000 | 292 | 100.00% | 100.00% |
| Feb. 14, 2024 | PHOENIX BIOTECH SPONSOR, LLC | TenPercentOwner | J | Warrants | 349998 | $0.00 | 0.0000 | 292 | 100.00% | 100.00% |
| Feb. 14, 2024 | Ehrlich Christopher B | Director | J | Common Stock | 1125000 | $0.00 | 4,653,671.0000 | 292 | 19.47% | 100.00% |
| Feb. 14, 2024 | Ehrlich Christopher B | Director | J | Common Stock | 4171246 | $0.00 | 1,482,425.0000 | 292 | 73.78% | 100.00% |
| Feb. 14, 2024 | Ehrlich Christopher B | Director | J | Common Stock | 3600 | $0.00 | 1,482,425.0000 | 292 | 0.24% | 100.00% |